SC 13D/A | 2023-03-30 | TVM Life Science Ventures VI LP | Acer Therapeutics Inc. | 248,756 | 1.1% | EDGAR |
SC 13G/A | 2023-02-14 | Nantahala Capital Management, LLC | Acer Therapeutics Inc. | 1,226,191 | 7.5% | EDGAR |
SC 13D/A | 2022-12-02 | Schelling Chris | Acer Therapeutics Inc. | 2,858,995 | 16.0% | EDGAR |
SC 13G/A | 2022-02-14 | Nantahala Capital Management, LLC | Acer Therapeutics Inc. | 901,290 | 6.3% | EDGAR |
SC 13G/A | 2021-02-12 | Nantahala Capital Management, LLC | Acer Therapeutics Inc. | 989,755 | 8.1% | EDGAR |
SC 13G/A | 2020-08-06 | HIRSCHMAN ORIN | Acer Therapeutics Inc. | 982,446 | 8.5% | EDGAR |
SC 13D/A | 2020-08-03 | Schelling Chris | Acer Therapeutics Inc. | 1,951,369 | 17.3% | EDGAR |
SC 13G | 2020-05-19 | HIRSCHMAN ORIN | Acer Therapeutics Inc. | 552,040 | 5.4% | EDGAR |
SC 13G/A | 2020-02-13 | Vivo Opportunity, LLC | Acer Therapeutics Inc. | 0 | 0.0% | EDGAR |
SC 13G/A | 2020-02-12 | Nantahala Capital Management, LLC | Acer Therapeutics Inc. | 990,655 | 9.8% | EDGAR |
SC 13D/A | 2019-04-19 | AVEGO HEALTHCARE CAPITAL, LLC | Acer Therapeutics Inc. | 111,526 | 1.1% | EDGAR |
SC 13G/A | 2019-02-14 | Vivo Opportunity, LLC | Acer Therapeutics Inc. | 579,051 | 5.8% | EDGAR |
SC 13G | 2019-02-14 | Nantahala Capital Management, LLC | Acer Therapeutics Inc. | 903,455 | 9.0% | EDGAR |
SC 13G | 2018-09-17 | Vivo Opportunity, LLC | Acer Therapeutics Inc. | 536,377 | 5.3% | EDGAR |
SC 13D/A | 2018-08-24 | TVM Life Science Ventures VI LP | Acer Therapeutics Inc. | 2,672,309 | 26.6% | EDGAR |
SC 13D/A | 2018-08-24 | TVM Life Science Ventures VI LP | Acer Therapeutics Inc. | 2,672,309 | 26.6% | EDGAR |
SC 13D | 2018-02-16 | TVM Life Science Ventures VI LP | Acer Therapeutics Inc. | 2,397,309 | 32.0% | EDGAR |
SC 13D | 2017-09-29 | Schelling Chris | Acer Therapeutics Inc. | 1,750,000 | 27.1% | EDGAR |
SC 13D | 2017-09-28 | AVEGO HEALTHCARE CAPITAL, LLC | Acer Therapeutics Inc. | 527,983 | 8.2% | EDGAR |
SC 13D/A | 2016-12-08 | Albert & Margaret Alkek Foundation | Opexa Therapeutics, Inc. | 14,904 | 0.2% | EDGAR |